| Literature DB >> 22650242 |
Daniel Merk1, Dieter Steinhilber, Manfred Schubert-Zsilavecz.
Abstract
The nuclear receptor farnesoid X receptor (FXR) has emerged as a highly promising target in preclinical development in recent years. A significant amount of research has been conducted and, although none has reached clinical use, many synthetic ligands of FXR have been described. This review outlines the available knowledge regarding the medicinal chemistry and SAR of these FXR ligands, and discusses the molecular interactions of the compounds with the FXR ligand-binding domain by interpreting the existing co-crystal structures.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22650242 DOI: 10.4155/fmc.12.47
Source DB: PubMed Journal: Future Med Chem ISSN: 1756-8919 Impact factor: 3.808